Navigation Links
Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR

HAYWARD, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today presented preclinical data on its proprietary nuclear export inhibitors (NEI) showing induction of potent, fast-acting and long-lasting anticancer activity with a high degree of tolerability in multiple human tumor xenograft cancer models.

Kosan's NEIs are potent, specific inhibitors of CRM1, a highly conserved, essential protein that exports key regulatory proteins ("cargo" proteins) from the nucleus to the cytoplasm. Many cargo proteins that depend on CRM1 for nuclear export, such as p53, Bcr-Abl and FOXO-3a, function as tumor suppressors or transcription factors that protect normal cells by regulating cell growth and apoptosis (cell death). Accumulation of these CRM1 cargo proteins in the nucleus, by blocking nuclear export, leads to the inhibition of cell growth and apoptosis selectively in cancer cells. Kosan's polyketide- based NEI compounds have optimized pharmaceutical properties, including potency, durability of action and a wide therapeutic index. Kosan anticipates becoming the first company to advance a nuclear export inhibitor into clinical development.

"We believe that Kosan has established an industry-leading position in NEI technology and has the only NEI inhibitor in late-stage preclinical development," said Pieter B.M.W.M. Timmermans, Ph.D., Kosan's Senior Vice President, Drug Discovery and Preclinical Development. "Our NEIs have demonstrated potent anticancer activity in human tumor xenograft models of breast, cervical, colon and non-small cell lung cancers, melanoma and leukemia, and have been shown to have robust efficacy in vivo at doses that are well-tolerated. We believe that NEIs represent a novel mechanism of action and have the potential to work additively and synergistically with a broad spectrum of cancer chemotherapies such as DNA-damaging agents that have limited durability
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... , Dec. 23, 2014  The American Diabetes ... pressure target for people with diabetes and that ... high doses of statins, in keeping with recent ... by the American College of Cardiology (ACC) and ... in the most recent changes to the Association,s ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Warner Chilcott plc (Nasdaq: WCRX ) announced today ... Inc. ("Par").  The Paragraph IV Certification Notice advises the Company of the ... generic version of the Company,s ASACOL 400 mg delayed release mesalamine product. ... ASACOL 400 mg, which ...
... RATON, Fla. , June 28 ... launch Anastrozole 1mg Tablets.  The U.S. Food and Drug Administration ... (ANDA) for this first time generic, which is being supplied ... Arimidex®, a billion dollar cancer drug marketed by AstraZeneca.  Breckenridge ...
Cached Medicine Technology:Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 3
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
(Date:12/25/2014)... The short film “Color of Honor” by ... of a true 9/11 hero, Welles Remy Crowther. It has ... 24 hours of Nuremberg International Short Film Festival and the ... Actress, screenwriter and director Luciana Lagana plays the mother ... her husband, Gregory Graham - Graham plays a ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 BambooFlooringChina.com sells ... high quality bamboo flooring. Today, the company announces ... in many styles and colors. , BambooFlooringChina.com is the ... CEO, the promotion is valid until Jan. 20, 2015. ... strips and woven with a natural thread. All the ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... of Dollars, GENEVA, SWITZERLAND, Feb. 11 ... will begin negotiations,here on an historic international treaty ... massive global problem that undermines efforts to reduce,tobacco ... and terrorist,organizations, and costs governments billions in revenue., ...
... LONDON, February 11 , - New Solution ... Efficiency, Misys plc (FTSE: MSY.L), the global ... in Pakistan has gone live with Misys,Equation. The ... revenues,reduce risk and drive business efficiency through processing, ...
... 11 MedThink Communications, an,innovator in medical ... been retained by Salix Pharmaceuticals, Inc, in,Morrisville ... under development, an,orally disintegrating form of metoclopramide., ... market the orally disintegrating,metoclopramide tablet and will ...
... Technology Into its ... ... the developer of,Software Lens(TM) technology, today announced a strategic cooperation ... integrates,Dblur,s Software Lens(TM) technology into STMicroelectronics, sensor and,camera module products., ...
... of Web pages dedicated to disseminating breast cancer information, ... Houston have determined that while most breast cancer data ... Web pages featured inaccuracies and sites displaying complementary and ... false or misleading health information. , Published in ...
... rest of the cells in your body, your red blood ... when mammals began to evolve. Other vertebrates such as fish, ... are inactive. Losing the nucleus enables the red blood cell ... be transported in the blood and boosting our metabolism. ...
Cached Medicine News:Health News:Nations to Launch Negotiations on Treaty to Combat Illicit Tobacco Trade 2Health News:Nations to Launch Negotiations on Treaty to Combat Illicit Tobacco Trade 3Health News:Nations to Launch Negotiations on Treaty to Combat Illicit Tobacco Trade 4Health News:Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 3Health News:Dblur Concludes Licensing Deal With STMicroelectronics 2Health News:Review of online breast cancer information encourages healthy skepticism for consumers 2Health News:How red blood cells nuke their nuclei 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: